Compare Cronos Group Inc (CRON) vs F5 Inc (FFIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs F5 Inc — how do they compare? Cronos Group Inc trades at $3.22 (market cap $1.18B), while F5 Inc trades at $471.08 (market cap $26.14B). The key difference: F5 Inc is far larger — about 22.2× Cronos Group Inc's market cap, and F5 Inc is trading nearer its 52-week high, Cronos Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and F5 Inc for 38 Days on average.
| CRON | FFIV | |
|---|---|---|
Market Cap | $1.18B | $26.14B |
Volume | 968,037 | 503,146 |
Sector | Health | Technology |
52-Week High | $3.55 | $469.79 |
52-Week Low | $2.30 | $223.99 |
Typical Hold Time | 22 Days | 38 Days |
Enterprise Value | $387.62M | $24.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.24, down 1.37% today amid a bearish technical signal. Recent quarterly earnings show beats in Q1 and Q2 2026, with revenue growth from $118M in 2024 to $147M in 2025. The company reported a net loss of $9.45M in 2025 but projects a profit of $70M for 2026. Analyst sentiment is mixed with a 20% buy rating. News highlights focus on international expansion and a recent Investor Day outlining growth strategies.
Outlook is cautiously optimistic given projected profitability in 2026 and strong cash reserves, but risks include sustained negative cash flow and competitive pressures. The stock's valuation metrics like P/E of 16.95 and P/S of 6.84 suggest moderate pricing relative to peers, though high EV/EBITDA of 43 indicates premium expectations.
F5 (FFIV) trades at $466.65, down 0.67% on the day, with strong technical momentum showing a bullish moving average signal despite overbought RSI readings. The company demonstrates robust fundamentals with revenue growth from $2.7B in 2022 to $3.1B in 2025 and expanding net margins reaching 22.42%. Recent recognition as a leader in IDC MarketScape for WAAP platforms and AI security innovations highlight competitive positioning.
FFIV presents a mixed outlook with strong earnings beats and profitability offset by premium valuations (P/E 36.78). Analyst consensus leans cautious with 41% buy ratings and $416.60 price target below current levels. Key risks include competitive pressures in application security and potential valuation compression if growth moderates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →
